{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:57:19Z","timestamp":1790801839746,"version":"4.1.0"},"reference-count":161,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Chemical Biology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.chembiol.2024.07.004","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T11:04:45Z","timestamp":1722942285000},"page":"1473-1489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Therapeutic potential of cis-targeting bispecific antibodies"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2920-9532","authenticated-orcid":false,"given":"Rob C.","family":"Oslund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela M.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Lesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olugbeminiyi O.","family":"Fadeyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chembiol.2024.07.004_bib1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.abg1209","article-title":"Bispecific antibodies","volume":"372","author":"Brinkmann","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.07.004_bib2","first-page":"18","article-title":"Biology drives the discovery of bispecific antibodies as innovative therapeutics","volume":"3","author":"Nie","year":"2020","journal-title":"Antib. Ther."},{"key":"10.1016\/j.chembiol.2024.07.004_bib3","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1126\/science.132.3441.1770","article-title":"Properties of the major component of a peptic digest of rabbit antibody","volume":"132","author":"Nisonoff","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.07.004_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1084\/jem.119.1.151","article-title":"SEROLOGIC DEMONSTRATION OF DUAL SPECIFICITY OF RABBIT BIVALENT HYBRID ANTIBODY","volume":"119","author":"Fudenberg","year":"1964","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.chembiol.2024.07.004_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s43141-021-00264-6","article-title":"Hybridoma technology; advancements, clinical significance, and future aspects","volume":"19","author":"Mitra","year":"2021","journal-title":"J.\u00a0Genet. Eng. Biotechnol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18010048","article-title":"Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies","volume":"18","author":"Yang","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.chembiol.2024.07.004_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2147\/DDDT.S151282","article-title":"Bispecific antibodies: design, therapy, perspectives","volume":"12","author":"Sedykh","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.chembiol.2024.07.004_bib8","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1158\/1535-7163.MCT-21-0073","article-title":"Targeting Solid Tumors Using CD3 Bispecific Antibodies","volume":"20","author":"Crawford","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.chembiol.2024.07.004_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.20892\/j.issn.2095-3941.2023.0002","article-title":"Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy","volume":"20","author":"Zhang","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.chembiol.2024.07.004_bib10","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.chembiol.2024.07.004_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib12","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","article-title":"Bispecific antibodies in cancer therapy: Target selection and regulatory requirements","volume":"13","author":"Sun","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.chembiol.2024.07.004_bib13","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.chembiol.2024.07.004_bib14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","article-title":"Faricimab: First Approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.chembiol.2024.07.004_bib15","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.chembiol.2024.07.004_bib16","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2024.07.004_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","article-title":"EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment","volume":"19","author":"Friedlaender","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ctrv.2013.06.002","article-title":"Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins","volume":"40","author":"Remon","year":"2014","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.chembiol.2024.07.004_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100641","article-title":"Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET","volume":"296","author":"Neijssen","year":"2021","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2024.07.004_bib20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/19420862.2016.1249079","article-title":"Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells","volume":"9","author":"Grugan","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.chembiol.2024.07.004_bib21","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s40265-022-01761-9","article-title":"Cadonilimab: First Approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.chembiol.2024.07.004_bib22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.chembiol.2024.07.004_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.chembiol.2024.07.004_bib24","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-20-1445","article-title":"Design and Efficacy of a Monovalent Bispecific PD-1\/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1(+) Activated T Cells","volume":"11","author":"Dovedi","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.chembiol.2024.07.004_bib25","doi-asserted-by":"crossref","first-page":"24689","DOI":"10.1074\/jbc.M115.651653","article-title":"Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor\u00a0\u00d7\u00a0c-MET Bispecific Antibody","volume":"290","author":"Jarantow","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2024.07.004_bib26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/19420862.2015.1136762","article-title":"Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody","volume":"8","author":"Zheng","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.chembiol.2024.07.004_bib27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ymeth.2013.07.017","article-title":"Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies","volume":"65","author":"Harms","year":"2014","journal-title":"Methods"},{"key":"10.1016\/j.chembiol.2024.07.004_bib28","doi-asserted-by":"crossref","first-page":"30189","DOI":"10.1021\/acsomega.1c02912","article-title":"Advances in Applications of Molecular Logic Gates","volume":"6","author":"Liu","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.chembiol.2024.07.004_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.chembiol.2024.07.004_bib30","first-page":"21","article-title":"Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It","volume":"10","author":"Luque-Cabal","year":"2016","journal-title":"Clin. Med. Insights Oncol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib31","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ccr.2011.09.003","article-title":"A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies","volume":"20","author":"Schaefer","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.chembiol.2024.07.004_bib32","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1158\/1535-7163.MCT-11-0820","article-title":"Antitumor activity of a novel bispecific antibody that targets the ErbB2\/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3","volume":"11","author":"McDonagh","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.chembiol.2024.07.004_bib33","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/sj.bjc.6604700","article-title":"Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in\u00a0vitro","volume":"99","author":"Robinson","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.chembiol.2024.07.004_bib34","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/1535-7163.MCT-13-0255","article-title":"MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors","volume":"13","author":"Fitzgerald","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.chembiol.2024.07.004_bib35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature05474","article-title":"Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3","volume":"445","author":"Sergina","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.07.004_bib36","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1158\/0008-5472.CAN-09-3145","article-title":"An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation","volume":"70","author":"Schoeberl","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.chembiol.2024.07.004_bib37","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","article-title":"Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements","volume":"12","author":"Schram","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.chembiol.2024.07.004_bib38","author":"Crescioli","year":"2024"},{"key":"10.1016\/j.chembiol.2024.07.004_bib39","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1073\/pnas.1819085116","article-title":"MM-131, a bispecific anti-Met\/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM","volume":"116","author":"Casaletto","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2024.07.004_bib40","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1038\/s41388-021-01714-8","article-title":"Oncogenic functions and therapeutic targeting of EphA2 in cancer","volume":"40","author":"Wilson","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.chembiol.2024.07.004_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.573823","article-title":"Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer","volume":"11","author":"Wei","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205187","article-title":"The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)\/CD166 in Human Solid Cancers","volume":"13","author":"Yang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.chembiol.2024.07.004_bib43","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41598-017-17539-z","article-title":"Cell-type specific potent Wnt signaling blockade by bispecific antibody","volume":"8","author":"Lee","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chembiol.2024.07.004_bib44","article-title":"A novel bispecific antibody for EGFR-directed blockade of the PD-1\/PD-L1 immune checkpoint","volume":"7","author":"Koopmans","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.chembiol.2024.07.004_bib45","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1158\/1535-7163.MCT-18-1313","article-title":"Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design","volume":"18","author":"Lee","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.chembiol.2024.07.004_bib46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11523-013-0290-9","article-title":"A\u00a0bispecific EpCAM\/CD133-targeted toxin is effective against carcinoma","volume":"9","author":"Waldron","year":"2014","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib47","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1535-7163.MCT-10-0203","article-title":"Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases","volume":"9","author":"Vallera","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.chembiol.2024.07.004_bib48","doi-asserted-by":"crossref","first-page":"25106","DOI":"10.1074\/jbc.M116.753491","article-title":"Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR)\u00a0\u00d7\u00a0c-MET Antibodies and Antibody-Drug Conjugates","volume":"291","author":"Sellmann","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2024.07.004_bib49","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1158\/1538-7445.AM2022-5284","article-title":"Abstract 5284: M1231 is a bispecific anti-MUC1xEGFR antibody-drug conjugate designed to treat solid tumors with MUC1 and EGFR co-expression","volume":"82","author":"Knuehl","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.chembiol.2024.07.004_bib50","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1158\/1538-7445.AM2023-2642","article-title":"Abstract 2642: BL-B01D1, a novel EGFR\u00d7HER3-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation","volume":"83","author":"Wan","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.chembiol.2024.07.004_bib51","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1158\/1535-7163.MCT-16-0364","article-title":"Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63","volume":"15","author":"de Goeij","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.chembiol.2024.07.004_bib52","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1158\/1535-7163.MCT-16-0658","article-title":"Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs","volume":"16","author":"Andreev","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.chembiol.2024.07.004_bib53","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1021\/acs.bioconjchem.7b00013","article-title":"Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates","volume":"28","author":"DeVay","year":"2017","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.chembiol.2024.07.004_bib54","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib55","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2310890","article-title":"Biparatopic antibodies: therapeutic applications and prospects","volume":"16","author":"Niquille","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.chembiol.2024.07.004_bib56","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","article-title":"An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity","volume":"14","author":"Weisser","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2024.07.004_bib57","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1+ 1> 2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.chembiol.2024.07.004_bib58","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.aan8630","article-title":"Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques","volume":"358","author":"Xu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.07.004_bib59","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1126\/science.aag3267","article-title":"A \"Trojan horse\" bispecific-antibody strategy for broad protection against ebolaviruses","volume":"354","author":"Wec","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.07.004_bib60","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1074\/jbc.RA117.001627","article-title":"Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins","volume":"293","author":"Nyakatura","year":"2018","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2024.07.004_bib61","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41587-022-01384-1","article-title":"Logic-gated antibody pairs that selectively act on cells co-expressing two antigens","volume":"40","author":"Oostindie","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138123","article-title":"Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity","volume":"10","author":"Holgate","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.chembiol.2024.07.004_bib63","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s00432-015-1949-7","article-title":"A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR","volume":"141","author":"Zeng","year":"2015","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib64","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/acscentsci.3c00395","article-title":"Proximity-Based Modalities for Biology and Medicine","volume":"9","author":"Liu","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.chembiol.2024.07.004_bib65","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41573-023-00833-z","article-title":"Extracellular targeted protein degradation: an emerging modality for drug discovery","volume":"23","author":"Wells","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chembiol.2024.07.004_bib66","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.07.004_bib67","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib68","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/acscentsci.1c00146","article-title":"Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins","volume":"7","author":"Zhou","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.chembiol.2024.07.004_bib69","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41587-022-01456-2","article-title":"Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins","volume":"41","author":"Pance","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib70","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.chembiol.2024.07.004_bib71","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1021\/acschembio.2c00185","article-title":"Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins","volume":"17","author":"Gramespacher","year":"2022","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib72","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-022-05235-6","article-title":"Antibody targeting of E3 ubiquitin ligases for receptor degradation","volume":"610","author":"Marei","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.07.004_bib73","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/acssynbio.2c00587","article-title":"Receptor Elimination by E3\u00a0Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox","volume":"12","author":"Siepe","year":"2023","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib74","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41586-020-2851-2","article-title":"Immune receptor inhibition through enforced phosphatase recruitment","volume":"586","author":"Fernandes","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.07.004_bib75","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T\u00a0cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib76","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2023.41.16_suppl.3001","article-title":"BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study","volume":"41","author":"Zhang","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib77","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chembiol.2024.07.004_bib78","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2206751120","article-title":"Discovery of antibodies and cognate surface targets for ovarian cancer by surface profiling","volume":"120","author":"Schr\u00f6felbauer","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2024.07.004_bib79","first-page":"1512","article-title":"Global signatures of protein and mRNA expression levels","volume":"5","author":"de Sousa Abreu","year":"2009","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.chembiol.2024.07.004_bib80","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/msb.2010.106","article-title":"Defining the transcriptome and proteome in three functionally different human cell lines","volume":"6","author":"Lundberg","year":"2010","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib81","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrg3185","article-title":"Insights into the regulation of protein abundance from proteomic and transcriptomic analyses","volume":"13","author":"Vogel","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.chembiol.2024.07.004_bib82","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41576-020-0258-4","article-title":"mRNAs, proteins and the emerging principles of gene expression control","volume":"21","author":"Buccitelli","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.chembiol.2024.07.004_bib83","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","article-title":"On the Dependency of Cellular Protein Levels on mRNA Abundance","volume":"165","author":"Liu","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.07.004_bib84","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2019.12.023","article-title":"Quantitative Proteomics of the Cancer Cell Line Encyclopedia","volume":"180","author":"Nusinow","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.07.004_bib85","doi-asserted-by":"crossref","first-page":"E10988","DOI":"10.1073\/pnas.1808790115","article-title":"The in\u00a0silico human surfaceome","volume":"115","author":"Bausch-Fluck","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2024.07.004_bib86","series-title":"Proteomic and Metabolomic Approaches to Biomarker Discovery","first-page":"409","article-title":"Chapter 24 - Cell surface protein enrichment for biomarker and drug target discovery using mass spectrometry-based\u00a0proteomics","author":"Ye","year":"2020"},{"key":"10.1016\/j.chembiol.2024.07.004_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal3321","article-title":"A subcellular map of the human proteome","volume":"356","author":"Thul","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.07.004_bib88","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41580-018-0094-y","article-title":"Spatial proteomics: a powerful discovery tool for cell biology","volume":"20","author":"Lundberg","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/membranes13040409","article-title":"Current Methods for Identifying Plasma Membrane Proteins as Cancer Biomarkers","volume":"13","author":"de Jong","year":"2023","journal-title":"Membranes"},{"key":"10.1016\/j.chembiol.2024.07.004_bib90","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nmeth.2896","article-title":"Next-gen immunohistochemistry","volume":"11","author":"Rimm","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.chembiol.2024.07.004_bib91","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.2869","article-title":"Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry","volume":"11","author":"Giesen","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.chembiol.2024.07.004_bib92","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nm.3488","article-title":"Multiplexed ion beam imaging of human breast tumors","volume":"20","author":"Angelo","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2024.07.004_bib93","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41588-021-00978-w","article-title":"Large-scale integration of the plasma proteome with genetics and disease","volume":"53","author":"Ferkingstad","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.chembiol.2024.07.004_bib94","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s42255-020-00287-2","article-title":"Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals","volume":"2","author":"Folkersen","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.chembiol.2024.07.004_bib95","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-018-0175-2","article-title":"Genomic atlas of the human plasma proteome","volume":"558","author":"Sun","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.07.004_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006706","article-title":"Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease","volume":"13","author":"Folkersen","year":"2017","journal-title":"PLoS Genet."},{"key":"10.1016\/j.chembiol.2024.07.004_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/science.abj1541","article-title":"Mapping the proteo-genomic convergence of human diseases","volume":"374","author":"Pietzner","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.07.004_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002431","article-title":"Entropic tension in crowded membranes","volume":"8","author":"Lind\u00e9n","year":"2012","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib99","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/pro.2574","article-title":"Linking 3D and 2D binding kinetics of membrane proteins by multiscale simulations","volume":"23","author":"Xie","year":"2014","journal-title":"Protein Sci."},{"key":"10.1016\/j.chembiol.2024.07.004_bib100","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.bbamem.2013.10.019","article-title":"The Fluid-Mosaic Model of Membrane Structure: still relevant to understanding the structure, function and dynamics of biological membranes after more than 40 years","volume":"1838","author":"Nicolson","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.chembiol.2024.07.004_bib101","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.cell.2019.04.018","article-title":"The Lateral Organization and Mobility of Plasma Membrane Components","volume":"177","author":"Jacobson","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.07.004_bib102","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/35036052","article-title":"Lipid rafts and signal transduction","volume":"1","author":"Simons","year":"2000","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib103","doi-asserted-by":"crossref","first-page":"a001321","DOI":"10.1101\/cshperspect.a001321","article-title":"Membrane organization and dynamics in cell polarity","volume":"1","author":"Orlando","year":"2009","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib104","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000513","article-title":"Remodeling epithelial cell organization: transitions between front-rear and apical-basal polarity","volume":"1","author":"Nelson","year":"2009","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib105","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1007\/s00018-019-03169-3","article-title":"The role of polarisation of circulating tumour cells in cancer metastasis","volume":"76","author":"Heikenwalder","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.chembiol.2024.07.004_bib106","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2021.1967080","article-title":"Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials","volume":"10","author":"Kyuno","year":"2022","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.chembiol.2024.07.004_bib107","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41580-020-00298-7","article-title":"Cell-cell interfaces as specialized compartments directing cell function","volume":"21","author":"Belardi","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib108","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev-cellbio-120420-103941","article-title":"Cis Interactions of Membrane Receptors and Ligands","volume":"39","author":"Hui","year":"2023","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib109","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ni1043","article-title":"Cis association of Ly49A with MHC class I restricts natural killer cell inhibition","volume":"5","author":"Doucey","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib110","first-page":"7286","article-title":"T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment","volume":"183","author":"Cheung","year":"2009","journal-title":"J.\u00a0Immunol., 1950"},{"key":"10.1016\/j.chembiol.2024.07.004_bib111","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/2326-6066.CIR-17-0316","article-title":"PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface","volume":"6","author":"Chaudhri","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.chembiol.2024.07.004_bib112","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.celrep.2018.06.054","article-title":"Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells","volume":"24","author":"Zhao","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.chembiol.2024.07.004_bib113","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T\u00a0cell responses","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.07.004_bib114","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","article-title":"PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways","volume":"51","author":"Zhao","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.chembiol.2024.07.004_bib115","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn6373","article-title":"Cis interactions between CD2 and its ligands on T\u00a0cells are required for T\u00a0cell activation","volume":"7","author":"Li","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib116","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221391","article-title":"CTLA4 depletes T\u00a0cell endogenous and trogocytosed B7 ligands via cis-endocytosis","volume":"220","author":"Xu","year":"2023","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.chembiol.2024.07.004_bib117","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.immuni.2023.04.005","article-title":"cis-B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8(+) T\u00a0cell function and anti-tumor immunity","volume":"56","author":"Zhao","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.chembiol.2024.07.004_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.chembiol.2024.07.004_bib119","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies\u00a0to overcome the current roadblocks in CAR T\u00a0cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib120","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41589-021-00790-x","article-title":"Strategies for monitoring cell\u2013cell interactions","volume":"17","author":"Bechtel","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib121","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the\u00a0next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2024.07.004_bib122","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.955684","article-title":"Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity","volume":"3","author":"Michaud","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.chembiol.2024.07.004_bib123","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061660","article-title":"Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process","volume":"12","author":"Feola","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.chembiol.2024.07.004_bib124","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1007\/s00432-020-03404-6","article-title":"Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy","volume":"146","author":"Huang","year":"2020","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib125","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1126\/science.aay4106","article-title":"Microenvironment mapping via Dexter energy transfer on immune cells","volume":"367","author":"Geri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.07.004_bib126","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1039\/D2OB02103J","article-title":"Proteomic mapping of intercellular synaptic environments via flavin-dependent photoredox catalysis","volume":"21","author":"Bechtel","year":"2022","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.chembiol.2024.07.004_bib127","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41557-022-01057-1","article-title":"Targeted activation in localized protein environments via deep red photoredox catalysis","volume":"15","author":"Tay","year":"2023","journal-title":"Nat. Chem."},{"key":"10.1016\/j.chembiol.2024.07.004_bib128","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.1039\/D3SC00638G","article-title":"Targeted proximity-labelling of protein tyrosines via flavin-dependent photoredox catalysis with mechanistic evidence for a radical-radical recombination pathway","volume":"14","author":"Hope","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.chembiol.2024.07.004_bib129","article-title":"Multiscale photocatalytic proximity labeling reveals cell surface neighbors on and between cells","volume":"385:eadl5763","author":"Lin","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2024.07.004_bib130","first-page":"388","article-title":"Mass spectrometry accelerates membrane protein analysis","volume":"36","author":"Savas","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.chembiol.2024.07.004_bib131","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nbt0303-262","article-title":"The application of mass spectrometry to membrane proteomics","volume":"21","author":"Wu","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib132","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1007\/s00216-023-04584-z","article-title":"Emergence of mass spectrometry detergents for membrane proteomics","volume":"415","author":"Behnke","year":"2023","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.chembiol.2024.07.004_bib133","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1021\/acs.jproteome.2c00838","article-title":"An Introduction to Mass Spectrometry-Based Proteomics","volume":"22","author":"Shuken","year":"2023","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.chembiol.2024.07.004_bib134","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.stemcr.2020.03.017","article-title":"Cell-Surface Proteomics Identifies Differences in Signaling and Adhesion Protein Expression between Naive and Primed Human Pluripotent Stem Cells","volume":"14","author":"Wojdyla","year":"2020","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.chembiol.2024.07.004_bib135","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.devcel.2018.09.017","article-title":"Organellar Proteomics and Phospho-Proteomics Reveal Subcellular Reorganization in Diet-Induced Hepatic Steatosis","volume":"47","author":"Krahmer","year":"2018","journal-title":"Dev. Cell"},{"key":"10.1016\/j.chembiol.2024.07.004_bib136","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cels.2016.08.012","article-title":"A Portrait of the Human Organelle Proteome In Space and Time during Cytomegalovirus Infection","volume":"3","author":"Jean Beltran","year":"2016","journal-title":"Cell Syst."},{"key":"10.1016\/j.chembiol.2024.07.004_bib137","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-021-03592-2","article-title":"A proximity-dependent biotinylation map of a human cell","volume":"595","author":"Go","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2024.07.004_bib138","article-title":"Bispecific Antibodies: From Research to Clinical Application","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib139","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.chembiol.2024.07.004_bib140","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chembiol.2024.07.004_bib141","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.csbj.2020.05.006","article-title":"Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies","volume":"18","author":"Dickopf","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.chembiol.2024.07.004_bib142","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38\/CD3 Bispecific\u00a0T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release","volume":"25","author":"Zuch de Zafra","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.chembiol.2024.07.004_bib143","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097292","article-title":"Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig\u2122) proteins with unique activities","volume":"9","author":"Gu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.chembiol.2024.07.004_bib144","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chembiol.2024.07.004_bib145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21207496","article-title":"Toward Drug-Like Multispecific Antibodies by Design","volume":"21","author":"Sawant","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.chembiol.2024.07.004_bib146","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib147","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nbt1207-1369","article-title":"Isotype selection in antibody engineering","volume":"25","author":"Salfeld","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib148","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/cei.13545","article-title":"Isotype selection for antibody-based cancer therapy","volume":"203","author":"Vukovic","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib149","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","article-title":"Avidity in antibody effector functions and biotherapeutic drug design","volume":"21","author":"Oostindie","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chembiol.2024.07.004_bib150","doi-asserted-by":"crossref","first-page":"11337","DOI":"10.1074\/jbc.M116.714287","article-title":"A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets","volume":"291","author":"Rhoden","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2024.07.004_bib151","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/19420862.2015.1022695","article-title":"Insights into the molecular basis of a bispecific antibody's target selectivity","volume":"7","author":"Mazor","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.chembiol.2024.07.004_bib152","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrd.2018.75","article-title":"The promise and challenges of immune agonist antibody development in cancer","volume":"17","author":"Mayes","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chembiol.2024.07.004_bib153","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.drudis.2021.09.008","article-title":"Agonist antibody discovery: Experimental, computational, and rational engineering approaches","volume":"27","author":"Schardt","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.chembiol.2024.07.004_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102996","article-title":"A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity","volume":"60","author":"Ding","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.chembiol.2024.07.004_bib155","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add4947","article-title":"Anti-PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases","volume":"8","author":"Suzuki","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib156","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/s42003-023-05326-8","article-title":"Development of a 1:1-binding biparatopic anti-TNFR2 antagonist by reducing signaling activity through epitope selection","volume":"6","author":"Akiba","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib157","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.chembiol.2024.07.004_bib158","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ccell.2018.04.003","article-title":"Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade","volume":"33","author":"Geuijen","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.chembiol.2024.07.004_bib159","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.tibtech.2021.03.003","article-title":"Animal Immunization, in\u00a0Vitro Display Technologies, and Machine Learning for Antibody Discovery","volume":"39","author":"Laustsen","year":"2021","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.chembiol.2024.07.004_bib160","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.tips.2022.12.005","article-title":"Computational and artificial intelligence-based methods for antibody development","volume":"44","author":"Kim","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.chembiol.2024.07.004_bib161","article-title":"Atomically accurate de novo design of single-domain antibodies","author":"Bennett","year":"2024","journal-title":"bioRxiv"}],"container-title":["Cell Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945624003064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945624003064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T07:41:42Z","timestamp":1755243702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451945624003064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":161,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2451945624003064"],"URL":"https:\/\/doi.org\/10.1016\/j.chembiol.2024.07.004","relation":{},"ISSN":["2451-9456"],"issn-type":[{"value":"2451-9456","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of cis-targeting bispecific antibodies","name":"articletitle","label":"Article Title"},{"value":"Cell Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chembiol.2024.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}